Figures & data
Figure 1 (A) Closed iridocorneal angle observed with a slit lamp. (B) Closed iridocorneal angle observed by optical coherence tomography (OCT). (C) Open iridocorneal angle after phacoemulsification observed with a slit lamp. (D) Open iridocorneal angles after phacoemulsification observed by OCT.
![Figure 1 (A) Closed iridocorneal angle observed with a slit lamp. (B) Closed iridocorneal angle observed by optical coherence tomography (OCT). (C) Open iridocorneal angle after phacoemulsification observed with a slit lamp. (D) Open iridocorneal angles after phacoemulsification observed by OCT.](/cms/asset/04ce0b53-de93-4d52-96bf-2bbcbafeb6a7/doph_a_12176513_f0001_c.jpg)
Figure 2 Eyes subjected to phacoemulsification. (A) After glaucomatous crisis. (B) As prophylaxis for glaucoma. (C) After iridotomy.
![Figure 2 Eyes subjected to phacoemulsification. (A) After glaucomatous crisis. (B) As prophylaxis for glaucoma. (C) After iridotomy.](/cms/asset/87a6b25d-4fc8-4e37-b62b-26184ad87b17/doph_a_12176513_f0002_b.jpg)
Figure 3 Use of antiglaucomatous medication prior to crisis. (A) Eyes in use of medication. (B) Eyes without use of medication.
![Figure 3 Use of antiglaucomatous medication prior to crisis. (A) Eyes in use of medication. (B) Eyes without use of medication.](/cms/asset/82089128-23e5-4776-9877-a1500025dbe0/doph_a_12176513_f0003_b.jpg)